Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lovastatin: a new cholesterol-lowering agent.

J M McKenney1

  • 1School of Pharmacy, Medical College of Virginia-Virginia Commonwealth University, Richmond 23298.

Clinical Pharmacy
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2008
Same author

Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2008
Same author

Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters.

Journal of clinical pharmacology·2006
Same author

Patient education and compliance: how to make it cost-effective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

Commentary on Langley and McKenney Papers.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

Pharmacotherapy of dyslipidemia.

Cardiovascular drugs and therapy·2002

Lovastatin, a cholesterol-lowering drug, effectively reduces LDL and triglyceride levels in most patients with hypercholesterolemia. Further research is needed on its long-term safety and impact on heart disease.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Clinical Medicine

Background:

  • Lovastatin is the first marketed drug in the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor class.
  • It functions by competitively inhibiting HMG CoA reductase, disrupting cholesterol biosynthesis.

Purpose of the Study:

  • To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage, administration, and adverse effects of lovastatin.
  • To evaluate lovastatin's role in managing hypercholesterolemia.

Main Methods:

  • Review of existing literature on lovastatin.
  • Analysis of clinical trial data regarding efficacy and adverse effects.

Main Results:

  • Lovastatin decreases total and LDL cholesterol by 25-45% at daily doses of 20-80 mg.

Related Experiment Videos

  • It reduces triglycerides, VLDL cholesterol, and apolipoprotein B, while slightly increasing HDL cholesterol.
  • Effective in heterozygous familial and nonfamilial hypercholesterolemia; ineffective in homozygous familial hypercholesterolemia.
  • Common adverse effects include headache and gastrointestinal issues; 1.9% of patients discontinued due to elevated aminotransferase levels.

    • Conclusions:

    • Lovastatin is a highly effective treatment for primary hypercholesterolemia, representing a significant therapeutic advancement.
    • Long-term safety and effects on coronary heart disease require further investigation.